Our approach is intervention-specific. We identify which dimensions of disease are relevant to the mechanism, determine how they can be measured and construct a theratype hypothesis that can be tested and refined during development.
Phenotype
What can be observed
Phenotypes describe the observable expression of disease. They may include clinical symptoms, structural damage, imaging findings, metabolic characteristics, biomechanical factors and pain-processing features.
These dimensions are not mutually exclusive.
Clinical
Structural
Inflammatory
Metabolic
Mechanical
Post-traumatic
Progression
Pain-processing
Endotype
What biological processes are active
Endotype-oriented development seeks measurable evidence of the pathways contributing to disease activity, symptoms or progression. These mechanisms frequently overlap and may be better represented as continuous dimensions than as discrete subgroups.
Tissue remodelling
01Synovial inflammation
02Cartilage turnover
03Subchondral bone
04Angiogenesis
05Complement & coagulation
06Metabolic dysregulation
07Senescence
08Neurovascular biology
09Pain sensitisation
10Theratype
Who may respond to this intervention.
A theratype is an intervention-specific, testable responder hypothesis. It links the mechanism of action to the disease context, measurable biology, patient characteristics and outcomes most likely to demonstrate therapeutic effect.
Mechanism
Disease context
Measurable biology
Patient characteristics
Evidence strategy
= Theratype hypothesis
“A theratype is not a permanent patient label. It is a treatment-specific, testable responder hypothesis.”
From classification to development utility
Describe
Characterise the disease as it presents clinically and structurally.
Measure
Identify biomarkers and imaging features linked to the relevant mechanism.
Enrich
Select patients in whom the intervention has a greater probability of demonstrating effect.
Validate
Prospectively test the response hypothesis and refine it across development.
What we deliver
A precision strategy that becomes a decision.
- Precision-development strategy
- Mechanism-to-patient map
- Theratype hypothesis
- Biomarker context-of-use plan
- Imaging strategy
- Enrichment criteria
- Prospective validation plan
- Regulatory positioning
- Post hoc hypothesis assessment
- Companion diagnostic roadmap where justified
The objective is not to make osteoarthritis appear simpler than it is. The objective is to make the next development decision more precise.